Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
about
Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade gliomaCurrent standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsOpportunities and challenges for successful use of bevacizumab in pediatrics.Diffusion-weighted MRI as a biomarker for treatment response in gliomaLipid metabolism emerges as a promising target for malignant glioma therapy.Imaging biomarkers for antiangiogenic therapy in malignant gliomas.Advanced magnetic resonance imaging of the physical processes in human glioblastoma.Diffusion MRI quality control and functional diffusion map results in ACRIN 6677/RTOG 0625: a multicenter, randomized, phase II trial of bevacizumab and chemotherapy in recurrent glioblastoma.Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy - detecting illusive disease, defining response.Early treatment response in non-small cell lung cancer patients using diffusion-weighted imaging and functional diffusion maps--a feasibility studyBevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomasComparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumabIntegrated multimodal imaging of dynamic bone-tumor alterations associated with metastatic prostate cancer.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.An Update on the Approach to the Imaging of Brain Tumors.Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapyVascular change measured with independent component analysis of dynamic susceptibility contrast MRI predicts bevacizumab response in high-grade glioma.Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.Serial MR diffusion to predict treatment response in high-grade pediatric brain tumors: a comparison of regional and voxel-based diffusion change metricsEffects of perfusion on diffusion changes in human brain tumors.Phase II study of bevacizumab in combination with sorafenib in recurrent glioblastoma (N0776): a north central cancer treatment group trial.Investigation of the diffusion abnormality index as a new imaging biomarker for early assessment of brain tumor response to radiation therapy.Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.Update on bevacizumab and other angiogenesis inhibitors for brain cancer.MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.Choline-to-N-acetyl aspartate and lipids-lactate-to-creatine ratios together with age assemble a significant Cox's proportional-hazards regression model for prediction of survival in high-grade gliomas.Prognostic implication of progression pattern after anti-VEGF bevacizumab treatment for recurrent malignant gliomas.Clinical PET/MRI in neurooncology: opportunities and challenges from a single-institution perspective.18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab.Restriction spectrum imaging predicts response to bevacizumab in patients with high-grade glioma.Evaluation of pre-radiotherapy apparent diffusion coefficient (ADC): patterns of recurrence and survival outcomes analysis in patients treated for glioblastoma multiforme.Persistent diffusion-restricted lesions in bevacizumab-treated malignant gliomas are associated with improved survival compared with matched controls.Correlation of MRI-derived apparent diffusion coefficients in newly diagnosed gliomas with [18F]-fluoro-L-dopa PET: what are we really measuring with minimum ADC?Histogram analysis of apparent diffusion coefficient within enhancing and nonenhancing tumor volumes in recurrent glioblastoma patients treated with bevacizumab.Pretreatment ADC histogram analysis is a predictive imaging biomarker for bevacizumab treatment but not chemotherapy in recurrent glioblastoma.Lack of functional normalisation of tumour vessels following anti-angiogenic therapy in glioblastoma.Survival prediction based on qualitative MRI diffusion signature in patients with recurrent high grade glioma treated with bevacizumab.Imaging biomarkers guided anti-angiogenic therapy for malignant gliomas
P2860
Q26826862-41896AC3-4D3E-4DBE-BF62-CA9768A40011Q26853308-2B388779-FC06-40FD-8474-017B4F53D3C3Q30454883-99102949-AF45-4F72-8331-42112D6C0679Q30660991-E3B24B77-2A40-4EB6-83A5-6CBC8C0EEFA7Q30684049-6C19A510-2C72-4B5B-B0D0-7BD3F0D4E6E1Q30764736-3AB5EFAB-B4B9-4D2E-8616-195B24B28675Q30847284-EF177148-06F5-4830-A116-76EC94766357Q30891381-102F61DD-7E90-4043-9243-5F040775E9F8Q30907831-DA40CD15-8D70-4B93-8062-13FAD52D4ADBQ34302644-5662B038-6460-4578-9D82-1C955206D08CQ34807753-4E3BAAA1-1617-4762-9270-FE68B0FF9AE2Q35028897-32F8D3E0-2056-4019-BEF0-1CDFAAF163F8Q35598954-E7B5369F-29C6-446F-98D9-9DC70C922E30Q35771783-0B6A0EDB-EE99-422A-907E-B4538CF715D4Q36374577-A74EA024-737D-4747-8F72-F3261BA71226Q36627187-74E6790A-D154-4FD8-B5C3-3396E89272EDQ36713499-49B1F0B0-813D-4086-80AD-2ECF944A94C2Q36943903-279FB54B-6DD8-43FD-9FF2-F9C847A287DCQ37021537-D58B150D-4E12-4ED2-B3EC-DA1F0439D370Q37076089-E41F58A6-C2A0-41FD-A6EA-A262C7D2B650Q37407066-2C287789-2307-4AE9-BF0C-87919CC60536Q37409700-386AE12B-AE0D-4794-BA6C-1715E2402BD2Q37510450-B0A991B6-3A06-4726-8D52-1988DFE603D7Q38106370-80CFB4FE-312C-4484-BC14-E78B50C6C221Q39312420-02231CE6-5B6F-4DE0-ABCC-DF4F80310EB9Q40582144-1DC674AC-97F4-4055-8C2A-C6DCCB3B22A4Q40886583-CFD51B60-4EA3-47FC-BD2D-360A56293754Q41594601-72070DC1-B620-4E0F-A3F7-792D4D8497D8Q41877778-88F01FE5-42DC-46A6-8364-7BE41D234042Q42702318-52D0D03C-58AE-4E71-AE10-C5B52E69A1A8Q44500841-AED781C9-6174-4CBE-B24E-E06FAEEF8014Q46524386-FC65766C-E2A9-4A64-B161-5EE2BE807555Q48330252-31F5DB58-B5C5-4016-AA43-ECD544702441Q48787869-D6DBF20B-6F5D-44CA-97CD-420FF90BB81BQ48926325-064D7287-E9FD-4006-A506-009B0831E435Q50578662-C994FA22-5EEC-455A-83E3-C7651E84D422Q55035317-8924AD48-46A4-4C7E-B590-F613CEF5B72BQ57177114-2B8A68C2-C6A4-4E1D-AE0A-F41742AA3B95
P2860
Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab.
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Graded functional diffusion ma ...... toma treated with bevacizumab.
@ast
Graded functional diffusion ma ...... toma treated with bevacizumab.
@en
type
label
Graded functional diffusion ma ...... toma treated with bevacizumab.
@ast
Graded functional diffusion ma ...... toma treated with bevacizumab.
@en
prefLabel
Graded functional diffusion ma ...... toma treated with bevacizumab.
@ast
Graded functional diffusion ma ...... toma treated with bevacizumab.
@en
P2093
P2860
P356
P1433
P1476
Graded functional diffusion ma ...... toma treated with bevacizumab.
@en
P2093
Albert Lai
Benjamin M Ellingson
Kathleen M Schmainda
Paul S Mischel
Phioanh L Nghiemphu
Shadi Lalezari
Timothy F Cloughesy
Whitney B Pope
P2860
P304
P356
10.1093/NEUONC/NOR079
P577
2011-08-19T00:00:00Z